Financial Performance - The company's revenue for Q3 2024 was ¥424,109,317.94, a decrease of 24.41% compared to the same period last year[3]. - The net profit attributable to shareholders was ¥332,634.62, down 98.94% year-on-year, while the net profit after deducting non-recurring gains and losses was a loss of ¥9,256,728.63, a decrease of 138.36%[3]. - The total operating revenue for the third quarter of 2024 was CNY 1,322,234,413.75, a decrease from CNY 1,558,714,943.06 in the same period last year, representing a decline of approximately 15.1%[13]. - The net profit attributable to shareholders of the parent company for Q3 2024 is CNY 36,142,245.31, a decrease from CNY 96,300,179.22 in the same period last year, representing a decline of approximately 62.4%[15]. - The total operating profit for Q3 2024 is CNY 45,679,264.51, down from CNY 122,096,871.15 in Q3 2023, indicating a decrease of about 62.6%[14]. - The total profit for Q3 2024 is CNY 45,366,860.75, compared to CNY 114,984,252.65 in the same quarter last year, indicating a decrease of about 60.6%[14]. - The basic and diluted earnings per share for Q3 2024 are both CNY 0.0906, down from CNY 0.2506 in Q3 2023, reflecting a decrease of approximately 63.8%[15]. - The total comprehensive income for Q3 2024 is CNY 36,142,245.31, down from CNY 96,300,179.22 in the same period last year, indicating a decline of approximately 62.4%[15]. Assets and Liabilities - The total assets as of September 30, 2024, were ¥5,856,658,963.67, representing a 3.64% increase from the end of the previous year[3]. - The total current liabilities rose to CNY 1,178,469,168.74, compared to CNY 914,828,245.64 at the beginning of the year, indicating an increase of around 28.9%[13]. - The total liabilities increased, with accounts payable rising by 46.69% to ¥489,419,984.61, mainly due to increased project payments[6]. - The inventory level increased to CNY 238,623,488.82 from CNY 191,506,412.04, which is an increase of approximately 24.6%[12]. - The long-term equity investments decreased to CNY 205,708,779.46 from CNY 228,080,576.15, reflecting a decline of about 9.8%[12]. - The total non-current liabilities decreased to CNY 331,328,211.47 from CNY 376,105,110.15, indicating a reduction of about 11.9%[13]. Cash Flow - The company reported a net cash flow from operating activities of -¥9,039,204.85 for the year-to-date, a decline of 108.25% compared to the same period last year[3]. - The net cash flow from operating activities was -9,039,204.85 CNY, a significant decrease compared to 109,516,412.77 CNY in the same period last year[17]. - The net cash flow from investment activities was 654,043,833.73 CNY, a recovery from a negative cash flow of -1,702,905,186.79 CNY in the previous year[17]. - The net cash flow from financing activities was -173,228,040.84 CNY, contrasting with a positive cash flow of 2,178,782,314.79 CNY in the same quarter last year[17]. - The total cash inflow from investment activities reached 3,431,165,537.51 CNY, up from 1,927,064,684.89 CNY year-over-year[17]. - The cash inflow from the recovery of investments was 3,347,000,000.00 CNY, significantly higher than 1,916,000,000.00 CNY in the previous year[17]. - The company received 84,071,034.15 CNY in cash from investment income, compared to 10,635,991.88 CNY in the same quarter last year[17]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 34,349[8]. - The largest shareholder, Yan Xiaohui, holds 22.15% of shares, totaling 88,585,200 shares, which are fully pledged[8]. - The second-largest shareholder, Yin Guoping, owns 16.04% of shares, amounting to 64,155,000 shares, with no pledges[8]. - The company has a total of 10,628,800 shares held by the Hubei Hongyuan Charity Foundation, representing 2.66% of shares[8]. - The report indicates that there are no changes in the top 10 shareholders due to margin trading activities[9]. - The number of restricted shares held by Yan Xiaohui remains at 88,585,200, with no releases during the reporting period[9]. - The company has a total of 19,759,950 unrestricted shares held by Xu Shuangxi, which will be released on September 20, 2024[9]. - The report confirms that there are no related party transactions among the top shareholders[9]. - The company has no preferred shareholders or changes in preferred shares during the reporting period[9]. - The report indicates that the company is maintaining its current shareholder structure without any new strategic initiatives or acquisitions mentioned[10]. Income and Expenses - The company's other income decreased by 48.93% to ¥12,027,805.99, primarily due to a reduction in government grants and subsidies[7]. - The company reported an asset impairment loss of ¥23,384,990.53, an increase of 124.72% compared to the previous year, primarily due to increased inventory write-downs[7]. - Research and development expenses for Q3 2024 amount to CNY 41,660,613.38, compared to CNY 49,373,159.61 in Q3 2023, reflecting a reduction of approximately 15.6%[14]. - The total operating costs for Q3 2024 are CNY 1,265,739,711.39, an increase from CNY 1,156,434,332.78 in the previous year, marking an increase of about 9.4%[14]. - The income tax expense for Q3 2024 is CNY 9,224,615.44, compared to CNY 18,684,073.43 in Q3 2023, reflecting a decrease of about 50.7%[14]. - The financial expenses for Q3 2024 show a net income of CNY -547,104.70, an improvement from CNY -2,247,361.83 in Q3 2023[14].
宏源药业(301246) - 2024 Q3 - 季度财报